Piramal Pharma Reports Rs 10 Cr Net Profit in Q3
By Rediff Money Desk, NEWDELHI Jan 31, 2024 16:19
Piramal Pharma swings back to profitability with a Rs 10 crore net profit in Q3, driven by growth in contract development and manufacturing business.
New Delhi, Jan 31 (PTI) Piramal Pharma on Wednesday swung into the black by reporting a consolidated net profit of Rs 10 crore for the third quarter ended December 2023.
The Mumbai-based drug firm had reported a net loss of Rs 90 crore in the October-December period of the last fiscal.
Its revenue from operations rose to Rs 1,959 crore for the third quarter against Rs 1,716 crore in the year-ago period, Piramal Pharma said in a regulatory filing.
"We continue to build on our improved performance in FY24 with 14 per cent year-on-year (YoY) revenue growth in the third quarter, along with a significant improvement in EBITDA margin," Piramal Pharma Chairperson Nandini Piramal said.
The company's contract development and manufacturing business is delivering healthy growth, with robust order inflows, especially for differentiated offerings and innovation-related work, she added.
"We look forward to continuing our momentum in Q4 and ending the financial year on a positive note," Piramal noted.
Shares of the company ended 3.74 per cent up at Rs 144.20 apiece on BSE.
The Mumbai-based drug firm had reported a net loss of Rs 90 crore in the October-December period of the last fiscal.
Its revenue from operations rose to Rs 1,959 crore for the third quarter against Rs 1,716 crore in the year-ago period, Piramal Pharma said in a regulatory filing.
"We continue to build on our improved performance in FY24 with 14 per cent year-on-year (YoY) revenue growth in the third quarter, along with a significant improvement in EBITDA margin," Piramal Pharma Chairperson Nandini Piramal said.
The company's contract development and manufacturing business is delivering healthy growth, with robust order inflows, especially for differentiated offerings and innovation-related work, she added.
"We look forward to continuing our momentum in Q4 and ending the financial year on a positive note," Piramal noted.
Shares of the company ended 3.74 per cent up at Rs 144.20 apiece on BSE.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.12 ( -6.94)
- 50036964
- G V Films
- 0.89 ( -5.32)
- 31226243
- Srestha Finvest
- 0.93 (+ 4.49)
- 24171047
- Spicejet Ltd.
- 57.98 ( -7.66)
- 15606461
- GTL Infrastructure
- 2.21 ( -4.74)
- 11410915
MORE NEWS
Mylan Settles Patent Suit with Novo Nordisk...
Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a...
India-UAE Investment Treaty in Effect: Key...
India and UAE's Bilateral Investment Treaty (BIT) came into effect on August 31, 2024,...
Sensex, Nifty Rise in Early Trade: Global...
Indian stock markets rebounded in early trade on Monday, mirroring a global rally....